The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

University of Iowa Health Care is among only three academic medical centers in the nation, and the first in the Midwest, to offer what promises to be groundbreaking treatment for people who are ...

A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major ...

BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...

Mendelian randomization analysis of genome-wide association study data suggests schizophrenia and major depressive disorder may cause constipation. Constipation, a common and often debilitating ...

Statistically significantly effects were observed as early as week 1 and maintained throughout the study. Treatment with lumateperone significantly reduced depressive symptoms in patients with major ...